{"product_id":"cedars-sinai-research-updates-in-lymphoma-2025","title":"Cedars Sinai Research Updates in Lymphoma 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists, oncologists, pathologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eSpecialties – Hematology, Imaging, Internal Medicine, Oncology, Pathology \u0026amp; Laboratory Medicine, Radiation Oncology, Radiology, Surgery\u003c\/p\u003e\n\u003cp\u003eProfessions – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eThis conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, “How I Treat” sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003cp\u003eRecognize the utility of molecular testing in the classification and treatment of lymphoma\u003c\/p\u003e\n\u003cp\u003eIdentify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma\u003c\/p\u003e\n\u003cp\u003eDescribe new treatments under development including bi specific antibodies and CART therapies\u003c\/p\u003e\n\u003cp\u003eCollaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSaturday, October 18, 2025\u003c\/p\u003e\n\u003cp\u003eSession 1: Hot Topics in Clinical Lymphoma – Part I\u003c\/p\u003e\n\u003cp\u003eSession Chair: TBD\u003c\/p\u003e\n\u003cp\u003eFrontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates\u003c\/p\u003e\n\u003cp\u003eJoe Schroers-Martin, MD\u003c\/p\u003e\n\u003cp\u003eMatthew G. Mei, MD\u003c\/p\u003e\n\u003cp\u003eDual Targeting CART for Lymphoma\u003c\/p\u003e\n\u003cp\u003eAkil Merchant, MD\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003eSession 2: Hot Topics in Clinical Lymphoma – Part II\u003c\/p\u003e\n\u003cp\u003eSession Chair: Justin Darrah\u003c\/p\u003e\n\u003cp\u003eT-Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003eWen-Kai Weng, MD, PhD\u003c\/p\u003e\n\u003cp\u003eRole of Radiation Therapy in Lymphoma\u003c\/p\u003e\n\u003cp\u003eParag Sanghvi, MD\u003c\/p\u003e\n\u003cp\u003eLightning Round\u003c\/p\u003e\n\u003cp\u003eLightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)\u003c\/p\u003e\n\u003cp\u003eLunch and Networking\u003c\/p\u003e\n\u003cp\u003eLunch and Exhibits\u003c\/p\u003e\n\u003cp\u003eSession 3: Keynote \u0026amp; Basic Science Insights\u003c\/p\u003e\n\u003cp\u003eSession Chair: Akil Merchant, MD\u003c\/p\u003e\n\u003cp\u003eKEYNOTE ADDRESS: Spatial Profiling in Lymphoma Transformers: More than Meets the Eye\u003c\/p\u003e\n\u003cp\u003eMina Xu, MD\u003c\/p\u003e\n\u003cp\u003eMicroenvironment in Non-Hodgkin Lymphoma\u003c\/p\u003e\n\u003cp\u003eAnthony R Colombo, PhD\u003c\/p\u003e\n\u003cp\u003eHidden Opponents: The DLBCL Microenvironment\u003c\/p\u003e\n\u003cp\u003eDavid Russler-Germain, MD, PhD\u003c\/p\u003e\n\u003cp\u003eMetabolic Profiling and Modulation of the Lymphoma Microenvironment\u003c\/p\u003e\n\u003cp\u003eAkil Merchant, MD\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003eSession 4: Next Generation Diagnostics and Biomarkers\u003c\/p\u003e\n\u003cp\u003eSession Chair: Joseph C. Lownik, MD\u003c\/p\u003e\n\u003cp\u003eLymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling\u003c\/p\u003e\n\u003cp\u003eLisa M Rimsza, MD\u003c\/p\u003e\n\u003cp\u003eDeveloping an Automated Multiplex IF for Diagnostic\/Biomarker Use in Lymphoma\u003c\/p\u003e\n\u003cp\u003eJoseph C. Lownik, MD\u003c\/p\u003e\n\u003cp\u003eRole of ct DNA in Lymphoma\u003c\/p\u003e\n\u003cp\u003eBrian Sworder, MD, PhD\u003c\/p\u003e\n\u003cp\u003eAssessments and Therapies for Older Patients with Aggressive Lymphomas\u003c\/p\u003e\n\u003cp\u003eElizabeth Brem, MD\u003c\/p\u003e\n\u003cp\u003eMolecular Determinants of Sensitivity to Polatuzumab-Vedotin in DLBCL\u003c\/p\u003e\n\u003cp\u003eSean R Corcoran , MD, PhD\u003c\/p\u003e\n\u003cp\u003eAdjourn\u003c\/p\u003e\n\u003cp\u003eNetworking Reception\u003c\/p\u003e\n\u003cp\u003eNetworking Reception\u003c\/p\u003e\n\u003cp\u003eSunday, October 19, 2025\u003c\/p\u003e\n\u003cp\u003eSession 1: CAR-T Cell Therapy: Managing Complex Toxicities\u003c\/p\u003e\n\u003cp\u003eSession Chair: Hitomi Hosoya, MD, PhD\u003c\/p\u003e\n\u003cp\u003eMechanisms of Neurotoxicity with IEC and Bispecific Therapies\u003c\/p\u003e\n\u003cp\u003eJuliane Gust, MD, PhD\u003c\/p\u003e\n\u003cp\u003eIEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management\u003c\/p\u003e\n\u003cp\u003eHrishikesh Srinagesh, MD\u003c\/p\u003e\n\u003cp\u003eProphylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches\u003c\/p\u003e\n\u003cp\u003eCaspian Oliai, MD\u003c\/p\u003e\n\u003cp\u003eSecondary and T-cell Malignancies after CAR T-cell Therapy\u003c\/p\u003e\n\u003cp\u003eHitomi Hosoya, MD, PhD\u003c\/p\u003e\n\u003cp\u003eBreak and Exhibits\u003c\/p\u003e\n\u003cp\u003eSession 2: Clinical Debate–What is the Optimal Bridging Strategy for CAR-T Therapy\u003c\/p\u003e\n\u003cp\u003eSession Chair: Justin Darrah, MD\u003c\/p\u003e\n\u003cp\u003eIntro: Why bridging?\u003c\/p\u003e\n\u003cp\u003eJustin Darrah, MD\u003c\/p\u003e\n\u003cp\u003eRole of Bispecifics as Bridging\u003c\/p\u003e\n\u003cp\u003eJustin Darrah, MD\u003c\/p\u003e\n\u003cp\u003eRadiation as Bridging\u003c\/p\u003e\n\u003cp\u003eParag Sanghvi, MD\u003c\/p\u003e\n\u003cp\u003eOptimal Chemotherapy for Bridging\u003c\/p\u003e\n\u003cp\u003eDavid R. Oveisi, MD\u003c\/p\u003e\n\u003cp\u003eDebate and Discussion\u003c\/p\u003e\n\u003cp\u003eBREAK\/EXHIBITS\u003c\/p\u003e\n\u003cp\u003eSession 3: Next Generation Cellular Therapies for Lymphoma and Beyond (Non Accredited)\u003c\/p\u003e\n\u003cp\u003eSession Chair: Yvonne Chen, PhD\u003c\/p\u003e\n\u003cp\u003eNovel CART for Solid Tumors\u003c\/p\u003e\n\u003cp\u003eYvonne Chen, PhD\u003c\/p\u003e\n\u003cp\u003eInnovations in TIL Therapy\u003c\/p\u003e\n\u003cp\u003eGiri Ramsingh , MD\u003c\/p\u003e\n\u003cp\u003eMacrophage Based Therapies\u003c\/p\u003e\n\u003cp\u003eAnn Liu, Other\u003c\/p\u003e\n\u003cp\u003eEngineered Protein Circuits for Cancer Therapy\u003c\/p\u003e\n\u003cp\u003eMichael B. Elowitz, PhD\u003c\/p\u003e\n\u003cp\u003eClosing and Lunch\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405802492100,"sku":null,"price":39.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Cedars-Sinai-Research-Updates-in-Lymphoma-2025.jpg?v=1784216402","url":"https:\/\/medicalcoursespro.com\/products\/cedars-sinai-research-updates-in-lymphoma-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}